Do you want to find the latest evidence concerning mental ill-health in young people?
The Evidence Finder tool allows you to search published studies of treatment and prevention strategies for mental health and substance use issues in young people. You can use the filters to refine your search or browse by category.
Disorders - Social phobia
Wagner, Karen Dineen, Berard, Ray, Stein, Murray B., Wetherhold, Erica, Carpenter, David J., Perera, Phillip, Gee, Michelle, Davy, Katherine, Machin, Andrea
BACKGROUND: Social anxiety disorder is a debilitating, highly prevalent disorder in children and adolescents. If left untreated, it can interfere with emotional, social, and school functioning. OBJECTIVE: To evaluate the efficacy and tolerability of paroxetine in children and adolescents with social anxiety disorder. DESIGN AND SETTING: Multicenter, 16-week, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, outpatient study.Patients A total of 322 children (8-11 years of age) and adolescents (12-17 years of age) with social anxiety disorder as their predominant psychiatric illness.Intervention Eligible patients were randomized (1:1) to receive paroxetine (10-50 mg/d) or placebo. RESULTS: Four hundred twenty-five patients were screened, and 322 were randomized to treatment. Of these, 319 were included in the intention-to-treat population (paroxetine, n = 163; placebo, n = 156). At the week 16 last observation carried forward end point, the odds of responding (Clinical Global Impression-Improvement score of 1 or 2) were statistically significantly greater for paroxetine (77.6% response [125/161]) than for placebo (38.3% response [59/154]) (adjusted odds ratio, 7.02; 95% confidence interval, 4.07 to 12.11; P<.001). The proportion of patients who were "very much" improved (Clinical Global Impression-Improvement score of 1) was 47.8% (77/161) for paroxetine compared with 14.9% (23/154) for placebo. Adverse events occurring at an incidence of 5% or greater for paroxetine and twice that for placebo were insomnia (14.1% vs 5.8%), decreased appetite (8.0% vs 3.2%), and vomiting (6.7% vs 1.9%). Withdrawals due to adverse events were infrequent (5.5% [9/163] for paroxetine and 1.3% [2/156] for placebo). CONCLUSION: Paroxetine is an effective, generally well-tolerated treatment for pediatric social anxiety disorder.
Archives of General Psychiatry, 61(11) : 1153-62
- Year: 2004
- Problem: Social phobia (social anxiety disorder)
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Garcia-Lopez, Luis-Joaquin, Olivares, Jose, Turner, Samuel M., Beidel, Deborah C., Albano, Anne M., Sanchez-Meca, Julio
Examined the clinical significance and effect size of 3 multi-component treatments for social phobia in an adolescent population. 59 adolescents (aged 15-17 yrs) who met DSM-IV criteria for generalized social phobia were assigned to 3 experimental treatments (N=44; Social Effectiveness Therapy for Adolescents-Spanish version, Cognitive-Behavioral Group Therapy for Adolescents, or Therapy for Adolescents with Generalized Social Phobia) or a control condition (N=15). Assessments were conducted at pretest, posttest and after a 12-mo follow-up. Assessment measures included a broad range of scales to evaluate maladaptation, social skills, public speech, and self-esteem as well as cognitive and avoidance symptoms of social anxiety. Short-term and long-term results support the effectiveness of the treatments in contrast with the control condition according to high and very high effect sizes obtained. Further, outcomes based on clinical significance also show significant changes in contrast to control condition. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Psicologia Conductual Revista Internacional de Psicologia Clinica de las Salud, 10(2) : 371-385
- Year: 2002
- Problem: Social phobia (social anxiety disorder)
- Type: Controlled clinical trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Psychological Interventions (any)
, Cognitive & behavioural therapies (CBT)
, Other Psychological Interventions
The Research Unit on Pediatric Psychopharmacology Anxiety Study Group,
Drugs that selectively inhibit serotonin reuptake are effective treatments for adults with mood and anxiety disorders, but limited data are available on the safety and efficacy of serotonin-reuptake inhibitors in children with anxiety disorders. 128 children (aged 6-17 yrs) who met the criteria for social phobia, separation anxiety disorder, or generalized anxiety disorder, and who had received psychological treatment for 3 wks without improvement were studied. The children were randomly assigned to receive fluvoxamine or placebo for 8 wks and were evaluated with rating scales designed to assess the degree of anxiety and impairment. Children in the fluvoxamine group had a mean decrease of 9.7 points in symptoms of anxiety on the Pediatric Anxiety Rating Scale, as compared with a decrease of 3.1 points among children in the placebo group. On the Clinical Global Impressions-Improvement scale, 48 of 63 children in the fluvoxamine group had a response to the treatment, as compared with 19 of 65 children in the placebo group. It is concluded that fluvoxamine is an effective treatment for children and adolescents with social phobia, separation anxiety disorder, or generalized anxiety disorder. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
New England Journal of Medicine, 344(17) : 1279-1285
- Year: 2001
- Problem: Anxiety Disorders (any), Generalized Anxiety Disorder, Social phobia (social anxiety disorder)
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Selective serotonin reuptake inhibitors (SSRIs)
Gormally J, Varvil-Weld D. Raphael R. Sipps G.
The major purpose of this study was to compare the effects of three treatments of social anxiety: cognitive counseling, skills training, and a treatment that combined these two approaches. The results showed that compared with a wait-list control, the three treatments produced significantly greater improvement on three of the five outcome measures. All three procedures appeared equally effective, since no significant differences were obtained on any of the five general outcome measures. Changes in the targets of counseling (i.e., maladaptive cognitions and conversational skill) were also assessed. Whereas all treatments produced more change on maladaptive cognitions compared with the waiting list control group, the treatments providing cognitive counseling produced the most change. No differences between treatments or between the waiting list and the treatments were obtained on measures of conversational skill. These results are discussed in terms of Bandura's self-efficacy theory and the influence of both specific and nonspecific sources of improvement in counseling. The study also raises several potential hypotheses for future research, including the relation between type of deficit and treatment outcome and the pervasive versus situation-specific nature of anxiety problems for minimal daters.
Journal of Counseling Psychology, 28(2) : 147-57
- Year: 1981
- Problem: Social phobia (social anxiety disorder)
- Type: Randomised controlled trials
-
Stage: At risk (indicated or selected prevention)
-
Treatment and intervention: Psychological Interventions (any)
, Skills training, Other Psychological Interventions